National Academy of Medicine Releases Report on Clinician Burnout – ASH Clinical News
National Academy of Medicine Releases Report on Clinician Burnout – Latest & Greatest – ASH Clinical News
Related Articles
Isatuximab Can Be Given as a Shorter Intravenous Infusion to Patients With Multiple Myeloma, New Trial Shows | ASH Clinical News | American Society of Hematology
Anna Azvolinsky is a science and health journalist based in New York City. A new clinical trial has found that a 30-minute intravenous (IV) infusion…
Relapse-Free Survival Progressively Shortens in Black Patients With Rituximab-Treated iTTP | ASH Clinical News | American Society of Hematology
Katie Robinson is a medical writer based in New York. In patients with relapsing immune thrombotic thrombocytopenic purpura (iTTP), successive rituximab treatment shortens relapse-free survival…
February 2025 | ASH Clinical News | American Society of Hematology
February 2025 | ASH Clinical News | American Society of Hematology February 2025 Thrown into Disarray The sudden withdrawal of voxelotor from the market left…
Anxiety, Depression Elevated in Patients with Histiocytic Neoplasms | ASH Clinical News | American Society of Hematology
Lara C. Pullen, PhD, is a freelance medical writer in Chicago, Illinois. While previous research has documented high levels of anxiety and depression in patients…
ASH Clinical News: February 2025 From the Desk Of…
Editor-in-Chief Aaron Gerds, MD, previews what’s to come in ASH Clinical News. Highlights of the February issue include a feature on the recent withdrawal of…
R/R ALL Treatment Receives FDA Approval | ASH Clinical News | American Society of Hematology
Obecabtagene autoleucel received approval from the U.S. Food and Drug Administration (FDA) for the treatment of relapsed or refractory (R/R) B-cell precursor acute lymphoblastic leukemia…
Oral Solution Imatinib Receives FDA Approval for Several Hematologic Diseases | ASH Clinical News | American Society of Hematology
Imatinib oral solution received U.S. Food and Drug Administration (FDA) approval for the treatment of chronic myeloid leukemia, acute lymphoblastic leukemia, and myelodysplastic syndromes/myeloproliferative neoplasms.…
January 2025 | ASH Clinical News | American Society of Hematology
January 2025 | ASH Clinical News | American Society of Hematology January 2025 Health Care Handcuffed? The overturning of the Chevron doctrine, a decades-old precedent,…
MGUS Risk Assessment Over Time Yields Benefits, Study Shows | ASH Clinical News | American Society of Hematology
Thomas R. Collins is a medical journalist based in West Palm Beach, Florida. Using models to measure the progression risk of patients with monoclonal gammopathy…
Discontinuing Maintenance Therapy for Multiple Myeloma Is Feasible, New Study Shows | ASH Clinical News | American Society of Hematology
Anna Azvolinsky, PhD, is a freelance medical and science journalist based in New York City. Patients with multiple myeloma (MM) who discontinued maintenance therapy based…